MedTrace Logo

Outcomes of Purpura FULminans in Adults - The hOPeFUL Study

NCT03216577 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2018-03-09

No results posted yet for this study

Summary

Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. The mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of limb amputation. The hOPeFUL study aims at assessing the short and long term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans.

Conditions

  • Purpura Fulminans

Interventions

OTHER

Phone interview measuring health-related quality of life variables

A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.

Sponsors & Collaborators

  • Fondation de France

    collaborator OTHER

  • Henri Mondor University Hospital

    lead OTHER

Principal Investigators

  • Nicolas de Prost, MD, PhD · Henri Mondor University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-27
Primary Completion
2018-03-08
Completion
2018-03-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03216577 on ClinicalTrials.gov